Back to search results

A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)

Abroad (travel likely)RecruitingPHASE3

Conditions

Narcolepsy Type 1

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Alkermes Investigational Site, Miami, Florida, United States

  • Alkermes Investigational Site, Winter Park, Florida, United States

  • Alkermes Investigational Site, Atlanta, Georgia, United States

  • Alkermes Investigational Site, Macon, Georgia, United States

  • Alkermes Investigational Site, Lansing, Michigan, United States

  • Alkermes Investigational Site, St Louis, Missouri, United States

  • Alkermes Investigational Site, Cincinnati, Ohio, United States

  • Alkermes Investigational Site, Dallas, Texas, United States

  • Alkermes Investigational Site, San Antonio, Texas, United States

  • Alkermes Investigational Site, Sugar Land, Texas, United States

Study leads

  • Medical Director, MD

    Study Director

    Alkermes, Inc.

View source on ClinicalTrials.gov(opens in a new tab)